Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Endometrial cancer~* Patients must have been treated with at least one line of chemotherapy, but not more than two lines of chemotherapy, and experienced progressive disease~* At least one measurable lesion~* ECOG performance status less than or equal to 1~* Minimum life expectancy of 3 months~* Adequate renal and hepatic function~* Adequate bone marrow function~* Serum cholesterol \<350 mg/dL and triglycerides \< 400 mg/dL~* Able to understand and give written informed consent~* Females of childbearing potential must have a negative pregnancy test and use approved contraception from screening to 30 days after the last study drug is given~Exclusion Criteria:~* Two lines of chemotherapy for recurrent or metastatic disease~* Chemotherapy for recurrent or metastatic disease administered within six months of adjuvant therapy~* More than two lines of chemotherapy of any type~* Prior therapy with hormonal agents~* Women who are pregnant or lactating~* Presence of brain or other central nervous system metastases~* Prior therapy with rapamycin, rapamycin analogues or tacrolimus or known sensitivity to these agents~* Anticancer treatment (chemotherapy, radiotherapy) within 4 weeks prior to randomization~* Ongoing toxicity associated with prior anticancer therapy~* Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to randomization.~* Another primary malignancy within the past five years (except for non-melanoma skin cancer and cervical carcinoma in situ)~* Known Grade 3 or 4 hypersensitivity to macrolide antibiotics~* Significant uncontrolled cardiovascular disease~* Active infection~* Known HIV infection~* Known Hepatitis B or C infection~* Newly diagnosed (within 3 months before enrollment) or poorly controlled Type 1 or 2 diabetes~* Concurrent treatment with immunosuppressive agents~* A requirement for concurrent treatment with medication that strongly induce or inhibit cytochrome P450 (CYP3A)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
- 2 (Type: ACTIVE_COMPARATOR): Investigator's choice of: oral medroxyprogesterone acetate tablets 200 mg daily or oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily) OR Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator

Based on this trial design, predict the completion outcome and termination type (if applicable).